A Randomized, Double-Blind, Placebo-Controlled, Dose-Titration, Safety, Tolerability, and Pharmacokinetics Study Followed by an Open-Label Safety and Efficacy Evaluation of SRP-4045 in Advanced-Stage Patients With Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping
Latest Information Update: 10 Nov 2025
At a glance
- Drugs Casimersen (Primary)
- Indications Duchenne muscular dystrophy
- Focus Adverse reactions; First in man
- Sponsors Sarepta Therapeutics
Most Recent Events
- 03 Oct 2025 According to a Sarepta Therapeutics media release, data from this trial will be presented at the 30th Annual Congress of the World Muscle Society (WMS) 2025 Congress, taking place Oct. 7-11, 2025, in Vienna, Austria.
- 01 Sep 2021 Results published in the Muscle and Nerve
- 22 Nov 2018 Status changed from active, no longer recruiting to completed.